XTalks

DECEMBER 13, 2023

3) Fulgent Genetics Compound annual growth rate: 260 percent Fulgent Genetics, headquartered in California, is a technology-driven company with a strong presence in clinical diagnostics and therapeutic development. The company achieved core revenues of $67 million, reflecting a remarkable 48 perecent year-over-year growth.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Scienmag

MAY 27, 2021

Capturing how RNA polymerase enzymes kick off transcription On scales too small for our eyes to see, the business of life happens through the making of proteins, which impart to our cells both structure and function.

Gene Expression 41

Gene Expression RNA DNA Protein 41

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company. From there, they evaluate what kind of antibodies are produced.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Scienmag

JULY 1, 2021

Almost twenty years ago, the process of RNA silencing was discovered in plants, whereby small fragments of RNA inactivate a portion of a gene during protein synthesis.

RNA 60

RNA Protein Research Gene 60

Scienmag

MARCH 4, 2021

Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.

Protein 46

Protein Medicine Drugs Research 46

STAT News

MARCH 6, 2023

But they said the sum covers only the direct costs of designing and manufacturing the vaccines ― which are tailored to the unique genetic makeup of each patient’s tumor ― and that the FDA has approved the breakdown of expenses. Neoantigen vaccines are designed to target certain proteins called neoantigens on tumor cells.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

The Pharma Data

JULY 27, 2021

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives.

Production 52

Production Antibody Sales Development 52

XTalks

NOVEMBER 7, 2022

Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations. Optimal methods for bioinformatic analysis are still needed. percent show less reliability). Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I Same with Alzheimer’s.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52